Dr. Albirini is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
955 Bethesda Dr FL 1
Zanesville, OH 43701Phone+1 740-454-0804Fax+1 740-454-7171
Education & Training
- SUNY Downstate Health Sciences UniversityFellowship, Cardiovascular Disease, 1996 - 1999
- Columbia Saint Luke's Medical CenterResidency, Internal Medicine, 1992 - 1995
- Damascus University Faculty of MedicineClass of 1989
Certifications & Licensure
- OH State Medical License 1994 - 2025
- NY State Medical License 1996 - 1999
- UT State Medical License 1994 - 1996
- American Board of Internal Medicine Cardiovascular Disease
- American Board of Internal Medicine Interventional Cardiology
Publications & Presentations
PubMed
- 578 citationsPrasugrel versus clopidogrel for acute coronary syndromes without revascularizationMatthew T. Roe, Paul W. Armstrong, Keith A.A. Fox, Harvey D. White, Dorairaj Prabhakaran
The New England Journal of Medicine. 2012-10-03 - 6 citationsClopidogrel is associated with better in-hospital and 30-day outcomes than ticlopidine after coronary stenting.Philippe L. L’Allier, Herbert D. Aronow, Fernando A. Cura, Deepak L. Bhatt, Abdulhay Albirini
The Canadian Journal of Cardiology. 2003-08-01 - 8 citationsPrognostic significance of creatine kinase-MB elevation after percutaneous coronary intervention in patients with chronic renal dysfunctionAllen Jeremias, Abdulhay Albirini, Khaled M. Ziada, Derek P. Chew, Sorin J. Brener
American Heart Journal. 2002-06-01
Press Mentions
- Genesis HealthCare System’s Institute Among the First in Ohio to Implement ProcedureOctober 12th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: